Related references
Note: Only part of the references are listed.Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer
Edmond M. Kwan et al.
JCO PRECISION ONCOLOGY (2021)
A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
Isabel Heidegger et al.
EUROPEAN UROLOGY ONCOLOGY (2021)
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Real World Experience With Pembrolizumab in Recurrent or Advanced Prostate Cancer
Julianna Higa et al.
CLINICAL GENITOURINARY CANCER (2020)
KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
Michael Paul Kolinsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics
Bastien Nguyen et al.
EUROPEAN UROLOGY (2020)
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer
Heidi Fettke et al.
EUROPEAN UROLOGY (2020)
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study.
Neeraj Agarwal et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer
Manish Kohli et al.
EBIOMEDICINE (2020)
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
Padmanee Sharma et al.
CANCER CELL (2020)
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors
Karim Fizazi et al.
EUROPEAN UROLOGY (2020)
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
Willemijn S M E Theelen et al.
Lancet Respiratory Medicine (2020)
When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials
Emmanuel S. Antonarakis et al.
EUROPEAN UROLOGY ONCOLOGY (2020)
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors
Emmanuel S. Antonarakis et al.
JCO PRECISION ONCOLOGY (2020)
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
Philipp Nuhn et al.
EUROPEAN UROLOGY (2019)
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
Ronald de Wit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma
Nora Sundahl et al.
EUROPEAN UROLOGY (2019)
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
Wassim Abida et al.
JAMA ONCOLOGY (2019)
Radiotherapy and immunotherapy: a synergistic effect in cancer care
Guy-Anne Turgeon et al.
MEDICAL JOURNAL OF AUSTRALIA (2019)
Safety Profile of Avelumab in Patients With Advanced Solid Tumors: A Pooled Analysis of Data From the Phase 1 JAVELIN Solid Tumor and Phase 2 JAVELIN Merkel 200 Clinical Trials
Karen Kelly et al.
CANCER (2018)
KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
Johann S. De Bono et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Alternative splicing in prostate cancer
Alec Paschalis et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Systematic Review of Immune Checkpoint Inhibition in Urological Cancers
Maud Rijnders et al.
EUROPEAN UROLOGY (2017)
Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
Farhad Fakhrejahani et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Tomasz M. Beer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Radiotherapy and immunotherapy: a beneficial liaison?
Ralph R. Weichselbaum et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Abscopal effects of radiation therapy: A clinical review for the radiobiologist
Shankar Siva et al.
CANCER LETTERS (2015)
Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions
Alexander Filatenkov et al.
CLINICAL CANCER RESEARCH (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
Andrew B. Sharabi et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon et al.
LANCET ONCOLOGY (2014)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment
Youjin Lee et al.
BLOOD (2009)
Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
M. Zahidunnabi Dewan et al.
CLINICAL CANCER RESEARCH (2009)
Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor
AA Lugade et al.
JOURNAL OF IMMUNOLOGY (2005)
Share Paper
